EyePoint Pharmaceuticals, Inc. (EYPT) Stock Forecast
EYPT analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 13 analysts
- Price target
- $25.91 average of analyst targets
- Upside to target
- +766.5% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.81
- 52-week range
- $2.99 – $18.85
EYPT analyst ratings
13 analystsNumber of analysts at each rating.
EYPT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EYPT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.92 | −$1.09 | −$0.60 | −$0.85 | −7.9% | 10 |
| Current fiscal year (2026) | −$3.64 | −$4.37 | −$2.70 | −$3.17 | −14.9% | 11 |
| Next fiscal year (2027) | −$2.78 | −$4.87 | −$1.06 | −$3.64 | +23.7% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EYPT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $252,500 | $0 | $600,000 | −73.9% | 12 |
| Current fiscal year (2026) | $1.7M | $700,000 | $2.7M | −94.7% | 13 |
| Next fiscal year (2027) | $17.9M | $0 | $88.0M | +967.2% | 13 |
EYPT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EYPT revenue: reported and forecast
EYPT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.81 | −$0.93 | −$0.91 | −$0.91 | −$0.92 | +12.8% | 1 up · 9 down |
| Current fiscal year (2026) | −$3.54 | −$3.85 | −$3.72 | −$3.72 | −$3.64 | +3.0% | 2 up · 9 down |
| Next fiscal year (2027) | −$2.91 | −$3.03 | −$2.77 | −$2.77 | −$2.78 | −4.4% | 5 up · 6 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EYPT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EYPT beat in 4 of 12.
What analysts expect from EYPT
13 analysts cover EyePoint Pharmaceuticals; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $25.91, 766.5% above the latest close of $2.99. Analysts expect earnings of −$3.64 per share for 2026, −14.9% from a year earlier. For 2027 the average estimate is −$2.78 per share on revenue of $17.9 million. EyePoint Pharmaceuticals beat the EPS estimate in 4 of the last 12 quarters.
Related: EYPT income statement, EYPT key metrics, EYPT chart. See the EYPT stock overview for the latest quote and news.
EYPT forecast FAQ
What is EyePoint Pharmaceuticals's price target?
The average analyst price target for EyePoint Pharmaceuticals is $25.91, 766.5% above the latest close of $2.99.
Is EyePoint Pharmaceuticals a buy, hold or sell?
Of 13 analysts covering EyePoint Pharmaceuticals, 6 rate it a strong buy, 1 a buy, 6 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is EyePoint Pharmaceuticals's EPS forecast?
Analysts forecast −$3.64 per share for 2026 (range −$4.37 to −$2.70); for 2027 the estimate is −$2.78.
What is EyePoint Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $1.7 million, growth of −94.7%; for 2027 it is $17.9 million.
When does EyePoint Pharmaceuticals report earnings?
EyePoint Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $-0.81.
Does EyePoint Pharmaceuticals usually beat earnings estimates?
EyePoint Pharmaceuticals reported EPS at or above the analyst estimate in 4 of the last 12 quarters.